Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

키워드

참고문헌 (18)

1. Hwang H, "Hepatocellular carcinoma with macrovascular invasion : need a personalized medicine for this complicated event", Hepatobiliary Surg Nutr, 13, pp.188~190 (2024)
2. Llovet JM, "Natural history of untreated nonsurgical hepatocellular carcinoma : rationale for the design and evaluation of therapeutic trials", Hepatology, 29, pp.62~67 (1999)
3. Khan AR, "Portal vein tumor thrombosis and hepatocellular carcinoma-The changing tides", J Hepatocell Carcinoma, 8, pp.1089~1115 (2021)
4. Yoon SM, "Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein : long-term patient outcomes", Int J Radiat Oncol Biol Phys, 82, pp.2004~2011 (2012)
5. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
6. Bruix J, "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma : Analysis of two phase III studies", J Hepatol, 67, pp.999~1008 (2017)
7. Song DS, "A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis", J Gastroenterol, 50, pp.445~454 (2015)
8. Cho Y, "Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma : An Asian perspective comparison", Clin Mol Hepatol, 29, pp.252~262 (2023)
9. Salem R, "Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres : a comprehensive report of long-term outcomes", Gastroenterology, 138, pp.52~64 (2010)
10. Korean Liver Cancer Association(KLCA)and National Cancer Center(NCC)Korea, "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clin Mol Hepatol, 28, pp.583~705 (2022)
11. Kulik LM, "Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis", Hepatology, 47, pp.71~81 (2008)
12. Hilgard P, "Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma : European experience on safety and long-term survival", Hepatology, 52, pp.1741~1749 (2010)
13. Spreafico C, "Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion", J Hepatol, 68, pp.724~732 (2018)
14. Vilgrain V, "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma(SARAH) : an open-label randomised controlled phase 3 trial", Lancet Oncol, 18, pp.1624~1636 (2017)
15. Chow PKH, "SIRveNIB : Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma", J Clin Oncol, 36, pp.1913~1921 (2018)
16. Garin E, "Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma(DOSISPHERE-01) : a randomised, multicentre, open-label phase 2 trial", Lancet Gastroenterol Hepatol, 6, pp.17~29 (2021)
17. Hur MH, "Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis", Clin Mol Hepatol, 29, pp.763~778 (2023)
18. Park J, "Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis", J Liver Cancer, 24, pp.81~91 (2024)

관련 논문AI추천